Htg Molecular Diagnostics, Inc.

John Wayne Cancer Institute

Krishna Maddula

Bruce Seligmann

Chris Cox

Dave S B Hoon

Hui Wang

Matt Rounseville

Ihab Botros

Bj Kerns

Tom Vasicek

Christopher Roberts

Zhenquiang Lu

B J Kerns

Bruce A Seligmann

Dave SB Hoon

Justin Brown

Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.

Molecular malignancy in melanocytic lesions

Disclosed herein are methods of co-detecting presence of target messenger RNA (mRNA) and small non-coding RNA (for example, miRNA) in a sample. The disclosed methods can be used to simultaneously detect mRNA and small non-coding RNA in a single assay (for example in the same reaction or the same well of a multi-well assay). The methods can include contacting a sample with a plurality of nuclease protection probes (NPPs) including at least one probe which specifically binds to a target mRNA and at least one probe which specifically binds to a target small non-coding RNA, contacting the sample with a nuclease specific for single-stranded nucleic acids, and detecting the NPP, for example on a microarray.

Methods of co-detecting MRNA and small non-coding RNA

Growing community of inventors

Tucson, AZ, United States of America

Krishna Maddula